Mol Neurobiol. 2025 Nov 14;63(1):39. doi: 10.1007/s12035-025-05372-9.
ABSTRACT
Neonatal hypoxic-ischemic brain damage (HIBD) is a devastating disease for which no treatments that effectively mitigate severe neurological consequences exist. Recent studies have shown that costunolide (COS), a well-known bioactive sesquiterpene lactone, possesses potent anti-inflammatory and neuroprotective properties, but its efficacy in the context of HIBD remains unclear. Here, we investigated the neuroprotective effects of COS in both in vivo and in vitro models of hypoxic-ischemic (HI) brain injury. In vivo, we found that COS intervention following a HI event dramatically reduced the brain infarction volume, ameliorated the inflammatory response, promoted histological recovery, and improved the prognosis. To explore the underlying molecular mechanisms, we performed an in vitro study and reported that COS protected PC12 cells from oxygen‒glucose deprivation (OGD) insult by reducing the levels of inflammatory mediators. Furthermore, COS activated the PI3K/AKT signaling pathway to suppress NF-κB and inflammation. In contrast, the PI3K inhibitor LY294002 reversed these therapeutic benefits. Our findings reveal that COS is a promising neuroprotective agent and could be used to treat HIBD and other related brain injuries.
PMID:41236577 | DOI:10.1007/s12035-025-05372-9
